Oligomer-specific conformations of the Human Immunodeficiency Virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies

AIDS Research and Human Retroviruses

Volumn 25, Issue 3, 2009, Pages 319-328

  Yuan, Wen ^a,g   Li, Xing ^b,c   Kasterka, Marta ^a   Gorny, Miroslaw K ^d   Zolla Pazner, Susan ^d,e   Sodroski, Joseph ^b,c,f  

^a UNIVERSITY OF VIRGINIA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; EPITOPE; GLYCOPROTEIN GP 41; HUMAN MONOCLONAL ANTIBODY; ISOLEUCINE; MONOCLONAL ANTIBODY; MUTANT PROTEIN; OLIGOMER; GP41 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DOMAIN; VIRUS ENVELOPE; CHEMISTRY; IMMUNOLOGY; MOLECULAR GENETICS; PROTEIN BINDING; PROTEIN MULTIMERIZATION;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; EPITOPES, B-LYMPHOCYTE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION;

EID: 65449174955     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0213     Document Type: Article

References (53)

1. Wyatt R and Sodroski J: The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 1998;280: 1884-1888.
2. Prabakaran P, Dimitrov AS, Fouts TR, and Dimitrov DS: Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors. Adv Pharmacol 2007;55:33-97.
3. Roux KH and Taylor KA: AIDS virus envelope spike structure. Curr Opin Struct Biol 2007;17:244-252.
4. Root MJ and Steger HK: HIV-1 gp41 as a target for viral entry inhibition. Curr Pharm Des 2004;10:1805-1825.
5. Hunter E: gp41, A multifunctional protein involved in HIV entry and pathogenesis. In: Human Retroviruses and AIDS 1997 (Korber B, Hahn B, Foley B, et al., eds.). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 1997, pp. III-55-73.
6. Yang X, Mahony E, Holm GH, Kassa A, and Sodroski J: Role of the gp120 inner domain beta-sandwich in the interaction between the human immunodeficiency virus envelope glycoprotein subunits. Virology 2003;313:117-125.
7. Chan DC and Kim PS: HIV entry and its inhibition. Cell 1998;93:681-684.
8. Binley JM, Ditzel HJ, Barbas CF 3rd, et al.: Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. AIDS Res Hum Retroviruses 1996;12:911-924.
9. Muster T, Steindl F, Purtscher M, et al.: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67:6642-6647.
10. Xu JY, Gorny MK, Palker T, Karwowska S, and Zolla-Pazner S: Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol 1991;65:4832-4838.
11. Zwick MB, Labrijn AF, Wang M, et al.: Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001;75:10892-10905.
12. Earl PL, Broder CC, Doms RW, and Moss B: Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J Virol 1997;71:2674-2684.
13. Gorny MK and Zolla-Pazner S: Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41. J Virol 2000;74:6186-6192.
14. Sattentau QJ, Zolla-Pazner S, and Poignard P: Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 1995;206:713-717.
15. Tyler DS, Stanley SD, Zolla-Pazner S, et al.: Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol 1990;145:3276-3282.
16. Zolla-Pazner S, O'Leary J, Burda S, et al.: Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. J Virol 1995; 69:3807-3815.
17. Moore PL, Crooks ET, Porter L, et al.: Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 2006;80:2515-2528.
18. Spear GT, Takefman DM, Sullivan BL, Landay AL, and Zolla-Pazner S: Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol 1993;67:53-59.
19. Gorny MK and Zolla-Pazner S: Human monoclonal antibodies that neutralize HIV-1. In: HIV Immunology and HIV/SIV Vaccine Databases 2003 (Korber BT, Brander C, Haynes BF, et al., eds.). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 2004, pp. 37-51.
20. Purtscher M, Trkola A, Gruber G, et al.: A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1994;10:1651-1658.
21. Trkola A, Pomales AB, Yuan H, et al.: Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995;69:6609-6617.
22. Hioe CE, Xu S, Chigurupati P, et al.: Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int Immunol 1997;9:1281-1290.
23. Alam SM, Scearce RM, Parks RJ, et al.: Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: Antibody binding kinetics, induction, and potential for regulation in acute infection. J Virol 2008;82:115-125.
24. Nelson JD, Kinkead H, Brunel FM, et al.: Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology 2008;377: 107-183.
25. Gustchina E, Louis JM, Lam SN, et al.: A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains. J Virol 2007;81:12946-12953.
26. Poignard P, Moulard M, Golez E, et al.: Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol 2003;77: 353-365.
27. Hurtley SM and Helenius A: Protein oligomerization in the endoplasmic reticulum. Annu Rev Cell Biol 1989;5:277-307.
28. Fouts TR, Binley JM, Trkola A, Robinson JE, and Moore JP: Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J Virol 1997;71:2779-2785.
29. Yuan W, Bazick J, and Sodroski J: Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker. J Virol 2006;80:6725-6737.
30. Yuan W, Craig S, Yang X, and Sodroski J: Inter-subunit disulfide bonds in soluble HIV-1 envelope glycoprotein trimers. Virology 2005;332:369-383.
31. Mische CC, Yuan W, Strack B, Craig S, Farzan M, and Sodroski J: An alternative conformation of the gp41 heptad repeat 1 region coiled coil exists in the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor. Virology 2005;338:133-143.
32. Cho MW: Subunit protein vaccines: Theoretical and practical considerations for HIV-1. Curr Mol Med 2003;3:243-263.
33. Kuiken CL, Foley B, Freed E, et al.: HIV Sequence Compendium 2002. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 2002, LA-UR 03-3564.
34. Gorny MK, Gianakakos V, Sharpe S, and Zolla-Pazner S: Generation of human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci USA 1989;86: 1624-1628.
35. Cavacini LA, Emes CL, Wisnewski AV, et al.: Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. AIDS Res Hum Retroviruses 1998;14:1271-1280.
36. Buchacher A, Predl R, Strutzenberger K, et al.: Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994;10:359-369.
37. Purtscher M, Trkola A, Grassauer A, et al.: Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. AIDS 1996;10:587-593.
38. Allan JS, Coligan JE, Barin F, et al.: Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 1985;228:1091-1094.
39. Moore JP: The reactivities of HIV-1+human sera with solidphase V3 loop peptides can be poor predictors of their reactivities with V3 loops on native gp120 molecules. AIDS Res Hum Retroviruses 1993;9:209-219.
40. Moore JP and Ho DD: Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol 1993;67:863-875.
41. Robey WG, Safai B, Oroszlan S, et al.: Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science 1985;228:593-595.
42. Wyatt R, Sullivan N, Thali M, et al.: Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J Virol 1993;67:4557-4565.
43. Pinter A, Honnen WJ, Tilley SA, et al.: Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J Virol 1989;63:2674-2679.
44. Das M and Fox CF: Chemical cross-linking in biology. Annu Rev Biophys Bioeng 1979;8:165-193.
45. Kyte J: Structure in Protein Chemistry. Garland Publishing, Inc., New York, 1995.
46. Wold F: Bifunctional reagents. Methods Enzymol 1972;25: 623-651.
47. Yang X, Lee J, Mahony EM, Kwong PD, Wyatt R, and Sodroski J: Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 2002; 76:4634-4642.
48. Jiang S, Lin K, and Lu M: A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J Virol 1998;72:10213-10217.
49. Broder CC, Earl PL, Long D, Abedon ST, Moss B, and Doms RW: Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: Oligomerspecific and -sensitive monoclonal antibodies. Proc Natl Acad Sci USA 1994;91:11699-11703.
50. de Rosny E, Vassell R, Jiang S, Kunert R, and Weiss CD: Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: Implications for fusion-inducing conformational changes. J Virol 2004;78:2627-2631.
51. Frey G, Peng H, Rits-Volloch S, Morelli M, Cheng Y, and Chen B: A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci USA 2008;105:3739-3744.
52. Ofek G, Tang M, Sambor A, et al.: Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004;78:10724-10737.
53. Si Z, Phan N, Kiprilov E, and Sodroski J: Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity. AIDS Res Hum Retroviruses 2003;19:217-226.